Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > New PR aroundVM

<< Previous

Bullboard Posts

Next >>

Comment by JayjayUSA12007on Oct 23, 2021 9:47pm

140 Views

Post# 34041480

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New PR aroundVM

"Is it possible Theras PDC could be used as an adjunct to other chemo drugs that have reduced efficacy due to VM.

https://scholar.google.ca/scholar?q=vascular+mimicry+effects+on+cancer+treatments&hl=en&as_sdt=0&as_vis=1&oi=scholart#d=gs_qabs&u=%23p%3DhYMFxg3j3CEJ "

Only when the neuroprotein sortilin are overexpressed on cancerous tumors.
1/ Breast, lung, and thyroid cancers: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496368/
2/ Pancreatic cancer: https://ascopost.com/news/august-2020/sortilin-may-be-a-potential-therapeutic-target-in-pancreatic-cancer/

If proven via clinical trials, TH1902 and TH1904 could become a anti-cancer platform. It won't take long before a big player will attempt to take out Thera, just to own this platform.